- Ultra-thinly traded nano cap Immuron Limited (NASDAQ:IMRN) is up 9% premarket on light volume on the heels of its announcement that the European Patent Office has issued it a patent covering the use of its enriched immunoglobulin preparation derived from colostrum for the treatment of nonalcoholic steatohepatitis (NASH).
- The patent will be in effect until April 2030.
Immuron nabs European patent for NASH treatment; shares up 9% premarket
Recommended For You
About IMRN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IMRN | - | - |
Immuron Limited |